In the context of melanoma, administration of autologous cDC2s (3–10 × 106 DCs) pulsed with tumor antigens (gp100, tyrosinase) in stage IV patients is non-toxic, well tolerated and induces the production of antigen-specific CD8+ T-cells in 30% of treated patients, 75% of whom survive without relapse for more than 15 months after the end of treatment [162]. The gene discussed is CD8A; the disease is melanoma.